Press Releases

Press Releases

Samsung Biologics obtains an Authorized Economic Operator (AEO) certificate

Samsung Biologics obtains an Authorized Economic Operator (AEO) certificate

 

 

Incheon, South Korea, October 22, 2018- Samsung Biologics, a global leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) based in South Korea, announced today that it has obtained an Authorized Economic Operator (AEO) issued by the World Customs Organization (WCO).
 
The AEO certification is granted by the customs authorities of each country to an excellent company that meets the four core criteria of compliance and internal control based on the World Customs Organization (WCO) export and import supply chain safety management standards. It is an international certification system which will enhance the business environment and further facilitate customs procedures.

 

By acquiring an AEO certification, Samsung Biologics has been able to reduce inventory costs by speeding up customs clearance including the reduction of inspection rate, elimination of document submission and so on since Oct. 15.

 

In particular, Samsung Biologics is expected to make contracts more through its improved import and export competitiveness as a global CDMO which imports most raw materials and exports all biopharmaceutical products.

 

Temperature-sensitive biopharmaceutical raw materials can be damaged if the customs procedure is prolonged, and if there is a sudden need for supply of the necessary raw materials, the production schedule may be disrupted.

 

For this reason, smooth customs clearance is essential for the improvement of production competitiveness in the case of the contract manufacturing organization (CMO), which receives mainly raw materials from overseas.

 

Companies that received AEO certification take advantages such as expedited shipment and customs simplification. AEO accredited companies can enjoy the same level of benefits in 19 countries around the world, including the United States, China, and Japan, which have signed the AEO MRA (Mutual Recognition Arrangement) agreement.

 

Samsung Biologics prepared the certificate with its internal task force (TF) for about 14 months. The TF team documented about 135 supplementary documents and 23 work standards in accordance with the AEO guidelines for the document review.

 

In May of this year, Korea Customs Service and the US Customs Trade Partnership Against Terrorism (C-TPAT) jointly held on-site inspection to examine cargo safety management, security systems, and procedures.

 

The joint inspection team highly evaluated Samsung Biologics’ employees understanding and uting procedures, systematic access control, personnel management, and information security.

 

Tae Han Kim, President and CEO of Samsung Biologics, said “With the acquisition of AEO certification, Samsung Biologics becomes more competitive in global business as rapid customs clearance is available.” He added “We will constantly endeavor for more stable supply chain management and innovate to provide biopharmaceuticals in timely manners for our clients and patients.”

 

Samsung Biologics obtains an Authorized Economic Operator (AEO) certificate

 

 

Incheon, South Korea, October 22, 2018- Samsung Biologics, a global leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) based in South Korea, announced today that it has obtained an Authorized Economic Operator (AEO) issued by the World Customs Organization (WCO).
 
The AEO certification is granted by the customs authorities of each country to an excellent company that meets the four core criteria of compliance and internal control based on the World Customs Organization (WCO) export and import supply chain safety management standards. It is an international certification system which will enhance the business environment and further facilitate customs procedures.

 

By acquiring an AEO certification, Samsung Biologics has been able to reduce inventory costs by speeding up customs clearance including the reduction of inspection rate, elimination of document submission and so on since Oct. 15.

 

In particular, Samsung Biologics is expected to make contracts more through its improved import and export competitiveness as a global CDMO which imports most raw materials and exports all biopharmaceutical products.

 

Temperature-sensitive biopharmaceutical raw materials can be damaged if the customs procedure is prolonged, and if there is a sudden need for supply of the necessary raw materials, the production schedule may be disrupted.

 

For this reason, smooth customs clearance is essential for the improvement of production competitiveness in the case of the contract manufacturing organization (CMO), which receives mainly raw materials from overseas.

 

Companies that received AEO certification take advantages such as expedited shipment and customs simplification. AEO accredited companies can enjoy the same level of benefits in 19 countries around the world, including the United States, China, and Japan, which have signed the AEO MRA (Mutual Recognition Arrangement) agreement.

 

Samsung Biologics prepared the certificate with its internal task force (TF) for about 14 months. The TF team documented about 135 supplementary documents and 23 work standards in accordance with the AEO guidelines for the document review.

 

In May of this year, Korea Customs Service and the US Customs Trade Partnership Against Terrorism (C-TPAT) jointly held on-site inspection to examine cargo safety management, security systems, and procedures.

 

The joint inspection team highly evaluated Samsung Biologics’ employees understanding and uting procedures, systematic access control, personnel management, and information security.

 

Tae Han Kim, President and CEO of Samsung Biologics, said “With the acquisition of AEO certification, Samsung Biologics becomes more competitive in global business as rapid customs clearance is available.” He added “We will constantly endeavor for more stable supply chain management and innovate to provide biopharmaceuticals in timely manners for our clients and patients.”

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION